How Theranos' faulty blood tests got to market – and what that shows about gaps in FDA regulation

One of the most high-profile trials of the year is underway to decide whether Theranos founder Elizabeth Holmes defrauded patients and investors.

Her blood testing startup, once valued at almost US$10 billion, was based on a seemingly revolutionary premise. Company executives promised investors, and later business partners…

© La Conversation - mardi 5 octobre 2021